SCLX
Scilex Holding Company
NASDAQ: SCLX · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$10.52
+21.76% today
Updated 2026-04-30
Market cap
$47.05M
P/E ratio
—
P/S ratio
1.56x
EPS (TTM)
$-36.48
Dividend yield
—
52W range
$4 – $34
Volume
0.0M
Scilex Holding Company (SCLX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $21.03M | $23.56M | $31.32M | $38.03M | $46.74M | $56.59M | $30.25M |
| Revenue growth (YoY) | — | +12.0% | +32.9% | +21.4% | +22.9% | +21.1% | -46.5% |
| Cost of revenue | $5.80M | $2.15M | $3.63M | $10.80M | $15.68M | $16.69M | $15.22M |
| Gross profit | $15.23M | $21.41M | $27.68M | $27.24M | $31.06M | $39.90M | $15.03M |
| Gross margin | 72.4% | 90.9% | 88.4% | 71.6% | 66.5% | 70.5% | 49.7% |
| R&D | $85.52M | $9.96M | $9.20M | $9.05M | $12.75M | $9.64M | $20.71M |
| SG&A | $64.70M | $42.97M | $50.58M | $64.89M | $119.64M | $119.02M | $266.88M |
| Operating income | $-138.69M | $-35.26M | $-35.84M | $-50.63M | $-105.43M | $-83.40M | $-272.30M |
| Operating margin | -659.4% | -149.7% | -114.4% | -133.1% | -225.6% | -147.4% | -900.1% |
| EBITDA | $-157.95M | $-31.48M | $-72.88M | $-9.30M | $-109.10M | $-66.80M | $-267.68M |
| EBITDA margin | -751.0% | -133.6% | -232.7% | -24.5% | -233.4% | -118.0% | -884.8% |
| EBIT | $-161.70M | $-35.26M | $-76.66M | $-13.76M | $-113.25M | $-70.84M | $-272.30M |
| Interest expense | $16.89M | $13.12M | $11.76M | $9.60M | $1.07M | $1.96M | $11.46M |
| Income tax | $2000.00 | $-53000.00 | $5000.00 | $4000.00 | $13000.00 | $-1000.00 | — |
| Effective tax rate | -0.0% | 0.1% | -0.0% | -0.0% | -0.0% | 0.0% | 0.0% |
| Net income | $-178.59M | $-47.52M | $-88.42M | $-23.36M | $-114.33M | $-72.81M | $-358.73M |
| Net income growth (YoY) | — | +73.4% | -86.1% | +73.6% | -389.3% | +36.3% | -392.7% |
| Profit margin | -849.1% | -201.7% | -282.4% | -61.4% | -244.6% | -128.7% | -1185.8% |